---
title: "ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298456935.md"
description: "ProQR Therapeutics announced the dosing of the first participant in its Phase 1 clinical trial for AX-0811, testing its ADAR-mediated Axiomer RNA editing platform. The study is conducted in Leiden, Netherlands, and Cambridge, Massachusetts, involving healthy volunteers. This milestone was announced on September 9, 2026."
datetime: "2026-09-09T12:02:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298456935.md)
  - [en](https://longbridge.com/en/news/298456935.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298456935.md)
generator: "portal-rs"
---

# ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

A clinical company ProQR Therapeutics N.V. has recently dosed the first participant in the Phase 1 clinical trial of AX-0811, which is being conducted in Leiden, Netherlands, and Cambridge, Massachusetts. This trial aims to test the RNA editing technology platform known as ADAR-mediated Axiomer™. ProQR is listed on Nasdaq as PRQR and focuses on developing transformative RNA therapies. The trial involves healthy volunteers and marks an important step in their journey to changing lives through innovative medical solutions. This milestone was announced on September 9, 2026.

### Related Stocks

- [PRQR.US](https://longbridge.com/en/quote/PRQR.US.md)

## Related News & Research

- [PRQR: AX-0811 entered the clinic, with five trial readouts and major AI-driven advances expected this year](https://longbridge.com/en/news/298484540.md)
- [ProQR reports Phase 1 target engagement for AX-0810 RNA editing drug in healthy volunteers](https://longbridge.com/en/news/290814522.md)
- [Baidu Steps Up Hong Kong Share Buybacks Under August 2026 Mandate](https://longbridge.com/en/news/299441763.md)
- [CoreWeave Stock (CRWV) Falls on $3B Convertible Debt Raise – Why Rosenblatt Remains Bullish](https://longbridge.com/en/news/299390217.md)
- [What's Going On With Sandisk Stock Friday?](https://longbridge.com/en/news/299469153.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**